AUPH — Aurinia Pharmaceuticals Inc. stock price, charts and financials
QT69Aurinia Pharmaceuticals Inc.Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
15.47
-0.38-2.37%
TA
Loading chart...
Snapshot
| Index | - | P/E | 6.69 | EPS (ttm) | 2.37 | Insider Own | 15.68% | Shs Outstand | 128.60M | Perf Week | 6.52% |
| Market Cap | 2.04B | Forward P/E | 12.93 | EPS next Y | 1.23 | Insider Trans | 8.50% | Shs Float | 126.24M | Perf Month | -4.46% |
| Enterprise Value | 1.92B | PEG | 0.01 | EPS next Q | 0.24 | Inst Own | - | Short Float | 7.70% | Perf Quarter | 4.69% |
| Income | 310.64M | P/S | 6.54 | EPS this Y | -55.56% | Inst Trans | - | Short Ratio | 6.52 | Perf Half Y | 11.15% |
| Sales | 311.50M | P/B | 3.35 | EPS next Y | 27.71% | ROA | 39.65% | Short Interest | 9.71M | Perf YTD | -0.63% |
| Book/sh | - | P/C | 9.97 | EPS next 5Y | 20.66% | ROE | 59.00% | 52W High | 18.79 -17.66% | Perf Year | 36.52% |
| Cash/sh | - | P/FCF | 9.87 | EPS past 3/5Y | - | ROIC | 21.27% | 52W Low | 10.09 53.29% | Perf 3Y | 56.47% |
| Dividend Est. | - | EV/EBITDA | 10.20 | Sales past 3/5Y | 28.30% 41.44% | Gross Margin | 90.36% | Volatility | 3.63% 3.59% | Perf 5Y | 16.89% |
| Dividend TTM | - | EV/Sales | 6.16 | EPS Y/Y TTM | 5396.18% | Oper. Margin | 48.39% | ATR (14) | 0.65 | Perf 10Y | 419.67% |
| Dividend Ex-Date | - | Quick Ratio | 4.97 | Sales Y/Y TTM | 26.81% | Profit Margin | - | RSI (14) | 53.30 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.42 | EPS Q/Q | 56.25% | SMA20 | 2.68% | Beta | 1.38 | Target Price | 16.00 |
| Payout | 0.00% | Debt/Eq | 0.10 | Sales Q/Q | 25.81% | SMA50 | -0.42% | Rel Volume | 1.03 | Prev Close | 15.85 |
| Employees | 128 | LT Debt/Eq | 0.10 | Earnings | Nov 03 | SMA200 | 3.95% | Avg Volume | 1.50M | Price | 15.47 |
| IPO Date | Sep 03, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 28.21% 0.94% | Net Debt/EBITDA | -0.63 | Volume | 1,545,178 | Change | -2.37% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | RBC Capital | Sector Perform | $15 → $16 |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform | $16 |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy | |
| Nov-05-25 | Downgrade | RBC Capital | Outperform → Sector Perform | $15 |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform | |
| Sep-06-24 | Reiterated | HC Wainwright & Co. | Buy | $26 → $13 |
| May-02-24 | Reiterated | Jefferies | $6.00 | |
| Jan-04-23 | Reiterated | RBC Capital | Outperform | $22 → $11 |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform | |
| Aug-09-22 | Reiterated | HC Wainwright & Co. | Buy | $30 → $26 |
Latest News
Aug-06-26
08:41AM
08:00AM
Jul-24-26
Jul-24-2605:00AM
Jul-23-26
Jul-22-26
Jul-06-26
Jul-06-2609:00AM
Jul-02-26
Jun-26-26
Jun-25-26
Jun-23-26
Jun-16-26
Company
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 311 | 283 | 235 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 31 | 33 | 28 | — | — | — | — | — | — | |
| Gross Profit | 282 | 250 | 207 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 101 | 102 | 172 | — | — | — | — | — | — | |
| Research and Development | 39 | 33 | 21 | — | — | — | — | — | — | |
| Other Operating Expense | -10 | 10 | 19 | — | — | — | — | — | — | |
| Operating Income | 150 | 105 | -5 | — | — | — | — | — | — | |
| Interest Expense | 9 | 4 | 5 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 14 | 17 | — | — | — | — | — | — | |
| Net Income Before Taxes | 161 | 114 | 7 | — | — | — | — | — | — | |
| Income Taxes | -154 | -173 | 2 | — | — | — | — | — | — | |
| Consolidated Net Income | 314 | 287 | 6 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 314 | 287 | 6 | — | — | — | — | — | — | |
| Net Income | 314 | 287 | 6 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.37 | 2.14 | 0.04 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.37 | 2.14 | 0.04 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.29 | 2.07 | 0.04 | — | — | — | — | — | — | |
| EBITDA | 189 | 128 | 32 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 6.76 | 7.71 | 228.50 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.47 | 7.55 | 5.46 | — | — | — | — | — | — | |
| Gross Margin | 90.68 | 88.34 | 88.09 | — | — | — | — | — | — | |
| Operating Margin | 48.23 | 37.10 | -2.13 | — | — | — | — | — | — | |
| Net Margin | 100.96 | 101.41 | 2.55 | — | — | — | — | — | — | |
| Shares Outstanding | 130 | 134 | 143 | — | — | — | — | — | — | |
| Market Capitalization | 2,012 | 2,137 | 1,284 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TANG KEVIN | Chief Executive Officer | Jun 02 '26 | Buy | 15.28 | 206,005 | 3,147,756 | 13,044,106 | Jun 02 |
| TANG KEVIN | Chief Executive Officer | Jun 01 '26 | Buy | 15.28 | 343,620 | 5,250,520 | 12,838,101 | Jun 02 |
| TANG KEVIN | Chief Executive Officer | May 29 '26 | Buy | 15.31 | 264,981 | 4,056,951 | 12,494,481 | Jun 02 |
| TANG KEVIN | Director | Mar 03 '26 | Buy | 14.22 | 184,208 | 2,619,438 | 12,229,500 | Mar 03 |
| TANG KEVIN | Director | Mar 02 '26 | Buy | 14.26 | 199,353 | 2,842,833 | 12,045,292 | Mar 03 |
| TANG KEVIN | Director | Feb 27 '26 | Buy | 13.99 | 516,439 | 7,226,535 | 11,845,939 | Mar 03 |
| TANG KEVIN | Director | Aug 05 '25 | Buy | 11.68 | 200,000 | 2,336,000 | 11,329,500 | Aug 05 |
| TANG KEVIN | Director | Aug 04 '25 | Buy | 11.34 | 100,000 | 1,134,000 | 11,129,500 | Aug 05 |
| TANG KEVIN | Director | Aug 01 '25 | Buy | 10.12 | 1,000,000 | 10,120,000 | 11,029,500 | Aug 05 |
| Keenan Greg | Chief Medical Officer | Aug 01 '25 | Sale | 10.50 | 20,000 | 210,000 | 133,484 | Aug 05 |
| Keenan Greg | Chief Medical Officer | Mar 07 '25 | Sale | 8.23 | 8,305 | 68,350 | 153,484 | Mar 07 |
| TANG KEVIN | Director | Mar 04 '25 | Buy | 7.96 | 748,038 | 5,953,304 | 10,029,500 | Mar 04 |
| Robertson Stephen P. | EVP, General Counsel | Mar 04 '25 | Sale | 7.92 | 57,607 | 456,247 | 509,276 | Mar 04 |
| Miller Joseph M | Chief Financial Officer | Mar 04 '25 | Sale | 7.92 | 56,154 | 444,740 | 577,361 | Mar 04 |
| Greenleaf Peter | Chief Executive Officer | Mar 04 '25 | Sale | 7.92 | 164,947 | 1,306,380 | 1,788,945 | Mar 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.